RESUMEN
Prompt diagnosis of lymphoma facilitates early treatment and improves outcomes for patients. For non-haemato-oncologists, it is important to have an understanding of how lymphoma can present and the initial work-up. This review is intended to provide clinicians with background to aid clinical decisional making at presentation and when managing treatment related complications. There will be particular emphasis on emergency presentations (tumour lysis syndrome, management of patients with a mediastinal mass, infections in lymphoma patients) and novel treatment options which have unique toxicities often requiring multi-specialty expertise.
Asunto(s)
Linfoma , Humanos , Linfoma/terapia , Linfoma/diagnóstico , Toma de Decisiones Clínicas , Síndrome de Lisis Tumoral/diagnóstico , Síndrome de Lisis Tumoral/terapia , Síndrome de Lisis Tumoral/etiologíaRESUMEN
BACKGROUND: Tumor lysis syndrome (TLS) is a hematologic oncological emergency characterized by metabolic and electrolyte imbalances. On breakdown of tumor cells, enormous amounts of potassium, phosphate, and nucleic acids are released into systemic circulation. TLS mainly occurs during chemotherapy. However, there are rare incidences of spontaneous tumor lysis syndrome (STLS) prior to commencement of therapy. CASE PRESENTATION: In the case being reported, the child had just undergone a biopsy. As the incision was being closed, there was a sudden onset of high fever, arrhythmia, severe hyperkalemia, hypocalcemia, and acidosis. Following timely symptomatic treatment and continuous renal replacement therapy(CRRT), the child's laboratory results improved, and organ function was restored to normal. The final pathological diagnosis confirmed Burkitt lymphoma. The boy is currently on maintenance chemotherapy. CONCLUSIONS: TLS is a potentially life-threatening complication in hematologic oncology. Several important conclusions can be drawn from this case, reminding clinicians to: (1) be fully aware of the risk factors of TLS and evaluate the level of risk; (2) pay attention to the possibility of STLS during operation, if surgical procedures are necessary and operate with minimal trauma and in the shortest time possibly; (3) take preoperative prophylaxis actively for high-risk TLS patients, including aggressive fluid management and rational use of diuretics and uric-acid-lowering drugs. In addition, this case confirms the effectiveness of CRRT for severe STLS.
Asunto(s)
Linfoma de Burkitt , Síndrome de Lisis Tumoral , Desequilibrio Hidroelectrolítico , Masculino , Niño , Humanos , Linfoma de Burkitt/complicaciones , Linfoma de Burkitt/diagnóstico , Linfoma de Burkitt/terapia , Síndrome de Lisis Tumoral/diagnóstico , Síndrome de Lisis Tumoral/etiología , Síndrome de Lisis Tumoral/terapia , Factores de Riesgo , Biopsia/efectos adversosRESUMEN
Hyperleukocytosis, a white blood cell count greater than 100,000/mcl, can be associated with the following three primary oncologic emergencies: leukostasis, disseminated intravascular coagulation, and tumor lysis syndrome. Th.
Asunto(s)
Leucemia Mieloide Aguda , Leucostasis , Síndrome de Lisis Tumoral , Humanos , Leucocitosis/diagnóstico , Leucocitosis/complicaciones , Pacientes Internos , Leucemia Mieloide Aguda/diagnóstico , Leucemia Mieloide Aguda/terapia , Leucemia Mieloide Aguda/complicaciones , Síndrome de Lisis Tumoral/diagnóstico , Síndrome de Lisis Tumoral/etiología , Síndrome de Lisis Tumoral/terapia , LeucaféresisRESUMEN
Background aims: B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor-T cell (CAR-T) therapy is used for refractory or relapsed multiple myeloma (r/r MM). However, CAR-T-related tumor lysis syndrome (TLS) has been observed. We aimed to elucidate the incidence, clinical and laboratory characteristics, and prognosis of CAR-T cell-related TLS. Methods: Patients (n=105) with r/r MM treated with BCMA-targeted CAR-T cell therapy were included. Patient characteristics, laboratory parameters, and clinical outcomes were assessed. Results: Eighteen (17.1%) patients developed TLS after BCMA-targeted CAR-T cell therapy. The median time till TLS onset was 8 days. Patients with TLS had steep rise in uric acid (UA), creatinine, and lactate dehydrogenase (LDH) within 6 days following CAR-T cell infusion and presented earlier and persistent escalation of cytokines (C-reactive protein [CRP], interleukin-6 [IL-6], interferon-γ [IFN-γ], and ferritin levels). All 18 patients had cytokine release syndrome (CRS), of which 13 (72.2%) developed grade 3-4 CRS. Three of 18 patients (16.7%) developed immune effector cell-associated neurotoxicity syndrome (ICANS): two patients with grade 1 ICANS and one with grade 2 ICANS. TLS development had a negative effect on the objective response rate (77.8% in the TLS group vs. 95.4% in the non-TLS group, p<0.01). During the median follow-up of 15.1 months, the median PFS was poorer of patients with TLS (median: 3.4 months in the TLS group vs. 14.7 months in the non-TLS group, p<0.001, hazard ratio [HR]=3.5 [95% confidence interval [CI] 1.5-8.5]). Also, TLS development exhibited significant effects on OS (median: 5.0 months in the TLS group vs. 39.8 months in the non-TLS group, p<0.001, hazard ratio [HR]=3.7 [95% CI 1.3-10.3]). TLS was associated with a higher tumor burden, elevated baseline creatinine and UA levels, severe CRS, pronounced CAR-T cell expansion, and corticosteroid use. Conclusion: TLS is a frequently observed CAR-T therapy complication and negatively influences clinical response and prognosis. Close monitoring for TLS should be implemented during CAR-T cell therapy, especially for those at high TLS risk.
Asunto(s)
Mieloma Múltiple , Receptores Quiméricos de Antígenos , Síndrome de Lisis Tumoral , Humanos , Mieloma Múltiple/tratamiento farmacológico , Antígeno de Maduración de Linfocitos B , Síndrome de Lisis Tumoral/etiología , Síndrome de Lisis Tumoral/terapia , Incidencia , Creatinina , Pronóstico , Tratamiento Basado en Trasplante de Células y TejidosRESUMEN
Cancer is a disease caused when cells divide uncontrollably and spread into surrounding tissues. There are different therapeutic modalities that control cancer growth, of which surgery, chemotherapy, and radiotherapy. Chemotherapy is a cancer treatment approach in which medications are used to inhibit cell proliferation and tumor multiplication, thus avoiding invasion and metastasis and thus eradicate cancer. One of the common complications associated with cancer chemotherapy is rapid lysis of expanding tumor cells, known as tumor lysis syndrome (TLS). TLS is associated with number of metabolic changes such as hyperuricemia, hyperkalemia, hyperphosphatemia and hypocalcemia. Among the consequences of hyperuricemia, hyperkalemia, hyperphosphatemia and hypocalcemia is the inhibition of 5' AMP-activated protein kinase (AMPK). Inhibition of AMPK induced different cancer chemo-resistance mechanisms such as cancer stem cells (CSCs), p-glycoproteins, Octamer-binding transcription factor 4 (OCT-4), homeobox protein NANOG, Krüppel-like factor 4 (KLF4) and immune microenvironment and thus leads to poor response to chemotherapy and even relapses after treatment. Our review aims to uncover new mechanisms underlying the metabolic consequences of tumor lysis on AMPK in tumor microenvironment. In this review, we also investigated the effect of AMPK on different cancer chemo-resistance mechanisms such as cancer stem cells, p-glycoproteins, OCT-4, NANOG, KLF4 and immune microenvironment.
Asunto(s)
Hiperpotasemia , Hiperfosfatemia , Hiperuricemia , Hipocalcemia , Síndrome de Lisis Tumoral , Humanos , Proteínas Quinasas Activadas por AMP , Resistencia a Antineoplásicos , Hiperpotasemia/complicaciones , Hiperpotasemia/terapia , Hiperfosfatemia/complicaciones , Hipocalcemia/complicaciones , Hipocalcemia/terapia , Recurrencia Local de Neoplasia , Síndrome de Lisis Tumoral/etiología , Síndrome de Lisis Tumoral/terapia , Microambiente Tumoral , Inhibidores de Proteínas Quinasas/uso terapéuticoRESUMEN
OBJECTIVE: To investigate the risk factors of tumor lysis syndrome (TLS) in relapsed/refractory multiple myeloma (MM) patients undergoing B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell therapy. METHOD: The clinical data of 99 relapsed/refractory MM patients receiving BCMA CAR-T cell therapy in the First Affiliated Hospital, Zhejiang University School of Medicine from July 2018 to December 2021 were collected in this study. Univariate analysis and multivariate logistic regression were performed to evaluate the risk factors of TLS following BCMA CAR-T cell therapy. RESULTS: Among the 99 patients, TLS occurred in 17 cases (17.2%) with an onset time of (8.9±3.0)â d after BCMA CAR-T cell therapy. All TLS patients developed TLS-related clinical manifestations, including 17 cases with renal dysfunction, 8 cases with arrhythmia. All TLS patients developed cytokine release syndrome (CRS) with an onset of 1.0 (1.0, 6.5) d after CAR-T cell therapy, and 13 cases developed grade 3-4 CRS. The levels of serum uric acid, serum creatinine and the ratio of cases with grade 3-4 CRS were significantly higher in TLS patients than in non-TLS patients (all P<0.05). Multivariate logistic regression revealed that serum creatinine ( OR=1.015, P<0.01) and severe CRS ( OR=9.371, P<0.01) were independent risk factors of TLS. CONCLUSIONS: Relapsed/refractory MM patients undergoing BCMA CAR-T therapy shows high incidence of TLS, which are related to elevated levels of serum creatinine and severe CRS. TLS can be prevented clinically by reducing serum creatinine and controlling CRS severity.
Asunto(s)
Mieloma Múltiple , Receptores Quiméricos de Antígenos , Síndrome de Lisis Tumoral , Antígeno de Maduración de Linfocitos B/uso terapéutico , Tratamiento Basado en Trasplante de Células y Tejidos , Creatinina , Humanos , Mieloma Múltiple/terapia , Receptores Quiméricos de Antígenos/uso terapéutico , Factores de Riesgo , Síndrome de Lisis Tumoral/etiología , Síndrome de Lisis Tumoral/terapia , Ácido ÚricoRESUMEN
BACKGROUND: Tumor lysis syndrome is a life-threatening oncologic emergency in adult and pediatric patients with hematologic cancer. It occurs most often in malignancies with rapid cell turnover and large tumor burden, but its incidence has risen in solid tumors. The subsequent release of tumor cell contents into the bloodstream results in dangerous electrolyte and metabolic disturbances. OBJECTIVE: To provide acute and critical care nurses with a comprehensive review targeted to critical care nursing practice. Recognition of hallmark signs and symptoms will improve early detection and intervention. METHODS: A literature review was performed using the following keywords: tumor lysis syndrome, diagnosis, nursing, early detection, and early diagnosis in PubMed and tumor lysis syndrome, diagnosis, early diagnosis, and early detection in CINAHL. Included studies were published in 2014 or later. RESULTS: Tumor lysis syndrome causes hyperkalemia, hyperphosphatemia, hypocalcemia, and hyperuricemia. These laboratory disturbances can lead to potentially destructive complications including renal injury, arrhythmias, seizures, and neuromuscular instability. DISCUSSION: Acute and critical care nurses can use disease-related risk factors and clinical presentations associated with these laboratory derangements to determine the level of monitoring and intervention necessary for impacted patients. CONCLUSIONS: Knowledge of risk factors and clinical presentations will enhance the ability of nurses in clinical practice to prevent adverse events and complications that result from tumor lysis syndrome.
Asunto(s)
Síndrome de Lisis Tumoral , Adulto , Niño , Humanos , Factores de Riesgo , Síndrome de Lisis Tumoral/diagnóstico , Síndrome de Lisis Tumoral/etiología , Síndrome de Lisis Tumoral/terapiaRESUMEN
Hematologic/Oncologic emergencies are rarely seen in the critical care transport environment but must be recognized and treated without delay. We report such a patient transported from a referring hospital to a tertiary care center by the LifePACT team, a 52-year-old male with a history of acute myeloid leukemia (AML). The patient presented to the referring hospital with known laboratory test abnormalities, suffered cardiac arrest, was resuscitated, accepted for transfer to a tertiary care center, and LifePACT was requested to perform the transport.
Asunto(s)
Coagulación Intravascular Diseminada , Leucemia Mieloide Aguda , Síndrome de Lisis Tumoral , Cuidados Críticos , Coagulación Intravascular Diseminada/terapia , Humanos , Masculino , Oncología Médica , Persona de Mediana Edad , Síndrome de Lisis Tumoral/etiología , Síndrome de Lisis Tumoral/terapiaRESUMEN
A new cancer diagnosis is expected to affect approximately 1.9 million people in the United States in 2021. A small percentage of these patients will experience an emergent cancer-related complication. Oncologic emergencies may be encountered in emergency departments or require intensive care management. Patients newly diagnosed with cancer are more likely to present with emergencies related to the underlying malignancies. Oncologic emergencies can have various manifestations, ranging from mechanical obstruction due to tumor growth to metabolic derangements due to abnormal secretions from the tumor. Therefore, early identification and treatment of life-threatening oncologic events is critical. Although there are several different types of oncologic emergencies, this article focuses on metabolic emergencies (tumor lysis syndrome and cytoreductive hyperthermic intraperitoneal chemotherapy) and structural emergencies (increased intracranial pressure and vena cava thrombus). The purpose of this article is to provide acute care clinicians with an overview of selected oncologic emergencies and their evidence-based management.
Asunto(s)
Neoplasias , Cuidados Críticos , Urgencias Médicas , Humanos , Neoplasias/complicaciones , Neoplasias/terapia , Síndrome de Lisis Tumoral/diagnóstico , Síndrome de Lisis Tumoral/terapia , Estados UnidosAsunto(s)
Crisis Blástica , Plaquetas , Leucemia Mieloide Aguda , Síndrome de Lisis Tumoral , Crisis Blástica/sangre , Crisis Blástica/patología , Crisis Blástica/terapia , Plaquetas/metabolismo , Plaquetas/patología , Femenino , Humanos , Leucemia Mieloide Aguda/sangre , Leucemia Mieloide Aguda/patología , Leucemia Mieloide Aguda/terapia , Persona de Mediana Edad , Síndrome de Lisis Tumoral/sangre , Síndrome de Lisis Tumoral/etiología , Síndrome de Lisis Tumoral/patología , Síndrome de Lisis Tumoral/terapiaRESUMEN
Tumour lysis syndrome (TLS) is a constellation of metabolic derangements caused by lysis of tumour cells. It is an oncological emergency that is considered a rare occurrence in multiple myeloma (MM) and usually occurs after patients have been treated with chemotherapy. We describe a very rare case of TLS occurring before the official diagnosis or treatment of MM. We report infrequent karyotype abnormalities, including loss of 17p13.1 (TP53 mutation), t(4;14) (FGFR3/IGH fusion) and monosomy 13, that have not been explicitly described in association with spontaneous tumour lysis syndrome (STLS) in MM. This case adds to the sparse literature available on STLS in MM, which is a life-threatening situation requiring urgent medical intervention.
Asunto(s)
Mieloma Múltiple/complicaciones , Síndrome de Lisis Tumoral/genética , Diagnóstico Diferencial , Quimioterapia Combinada , Resultado Fatal , Humanos , Masculino , Persona de Mediana Edad , Monosomía , Mieloma Múltiple/diagnóstico , Mieloma Múltiple/terapia , Diálisis Renal , Síndrome de Lisis Tumoral/diagnóstico , Síndrome de Lisis Tumoral/terapiaRESUMEN
Tumor lysis syndrome (TLS) is an oncologic emergency due to massive tumor cell lysis with the release of large amounts of potassium, phosphate, and nucleic acids into the systemic circulation. Clinical presentation is characterized by hyperkalemia, hyperphosphatemia, hyperuricemia, and hypocalcemia. Acute kidney injury due to tumor lysis is potentiated by the precipitation of uric acid and calcium phosphate as well as renal vasoconstriction. Early recognition of tumor lysis can help prevent cardiac arrhythmias, seizures, and death. Management includes intravenous hydration to maintain urine flow, medications targeting hyperuricemia including rasburicase and allopurinol and in severe cases renal replacement therapy may be required.
Asunto(s)
Hiperfosfatemia , Hiperuricemia , Síndrome de Lisis Tumoral , Alopurinol/uso terapéutico , Humanos , Hiperfosfatemia/tratamiento farmacológico , Hiperfosfatemia/terapia , Hiperuricemia/tratamiento farmacológico , Terapia de Reemplazo Renal , Síndrome de Lisis Tumoral/diagnóstico , Síndrome de Lisis Tumoral/etiología , Síndrome de Lisis Tumoral/terapia , Urato Oxidasa/uso terapéuticoRESUMEN
ABSTRACT: Tumor lysis syndrome (TLS) is one of the most common oncologic emergencies, occurring when tumor cell contents are rapidly released into the bloodstream. This release of cellular contents, including uric acid, phosphate, and potassium, can rapidly overwhelm the body's homeostasis mechanisms, leading to renal failure, seizures, cardiac dysrhythmias, or death. With an estimated 1.8 million new diagnoses of cancer projected in 2020 and an increase in the use of targeted agents for treatment, healthcare providers must be able to recognize, diagnose, and manage patients presenting with TLS.
Asunto(s)
Síndrome de Lisis Tumoral/diagnóstico , Síndrome de Lisis Tumoral/etiología , Arritmias Cardíacas/etiología , Urgencias Médicas , Homeostasis , Humanos , Hiperpotasemia/etiología , Hiperfosfatemia/etiología , Hiperuricemia/etiología , Hipocalcemia/etiología , Insuficiencia Renal/etiología , Convulsiones/etiología , Síndrome de Lisis Tumoral/terapiaRESUMEN
Chimeric antigen receptor T (CAR-T) cell therapy is a breakthrough in cancer treatment. With the widespread use of this therapy, increasing evidence is available that CAR-T cell therapy is associated with acute kidney injury (AKI). Nephrologists need to understand the potential nephrotoxicity arising from CAR-T cell therapy. Determining the cause of AKI is a key factor of clinical management. This review focuses on the clinical use of CAR-T cell therapy and the cause and outcomes of nephrotoxicity with its use. We also provide clinical suggestions for clinicians towards both better diagnosis and management of AKI in those receiving CAR-T cell therapy.
Asunto(s)
Lesión Renal Aguda/diagnóstico , Lesión Renal Aguda/terapia , Inmunoterapia Adoptiva/efectos adversos , Receptores Quiméricos de Antígenos/metabolismo , Linfocitos T/trasplante , Lesión Renal Aguda/inmunología , Animales , Síndrome de Liberación de Citoquinas/diagnóstico , Síndrome de Liberación de Citoquinas/inmunología , Síndrome de Liberación de Citoquinas/terapia , Diagnóstico Precoz , Humanos , Linfohistiocitosis Hemofagocítica/diagnóstico , Linfohistiocitosis Hemofagocítica/inmunología , Linfohistiocitosis Hemofagocítica/terapia , Pronóstico , Receptores Quiméricos de Antígenos/genética , Receptores Quiméricos de Antígenos/inmunología , Medición de Riesgo , Factores de Riesgo , Linfocitos T/inmunología , Linfocitos T/metabolismo , Síndrome de Lisis Tumoral/diagnóstico , Síndrome de Lisis Tumoral/inmunología , Síndrome de Lisis Tumoral/terapiaRESUMEN
Gemtuzumab ozogamicin (GO), a humanized anti-CD33 monoclonal antibody conjugated to the cytotoxic antibiotic agent calicheamicin, is approved for the treatment of newly-diagnosed CD33 + AML in adults and children ≥ 1 month old, and relapsed or refractory CD33 + AML in adults and children ≥ 2 years old. GO treatment has been associated with an increased risk of hepatotoxicity and hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS), especially following hematopoietic stem cell transplantation. Other non-specific serious adverse events (SAEs) associated with GO treatment are myelosuppression, bleeding/thrombocytopenia, infusion-related reaction, and tumor lysis syndrome. This report summarizes an expert panel of physicians' recommendations for the evaluation and management of SAEs following GO, emphasizing the prevention and management of VOD/SOS.
Asunto(s)
Antineoplásicos Inmunológicos/efectos adversos , Gemtuzumab/efectos adversos , Leucemia Mieloide Aguda/tratamiento farmacológico , Animales , Antineoplásicos Inmunológicos/uso terapéutico , Manejo de la Enfermedad , Gemtuzumab/uso terapéutico , Enfermedad Veno-Oclusiva Hepática/inducido químicamente , Enfermedad Veno-Oclusiva Hepática/prevención & control , Enfermedad Veno-Oclusiva Hepática/terapia , Humanos , Neutropenia/inducido químicamente , Neutropenia/prevención & control , Neutropenia/terapia , Trombocitopenia/inducido químicamente , Trombocitopenia/prevención & control , Trombocitopenia/terapia , Síndrome de Lisis Tumoral/etiología , Síndrome de Lisis Tumoral/prevención & control , Síndrome de Lisis Tumoral/terapiaRESUMEN
BACKGROUND: Tumor lysis syndrome (TLS) is an oncologic emergency due to a rapid break down of malignant cells usually induced by cytotoxic therapy, with hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia, and serious clinical consequences such as acute renal injury, cardiac arrhythmia, hypotension, and death. Rapidly expanding knowledge of cancer immune evasion mechanisms and host-tumor interactions has significantly changed our therapeutic strategies in hemato-oncology what resulted in the expanding spectrum of neoplasms with a risk of TLS. SUMMARY: Since clinical TLS is a life-threatening condition, identifying patients with risk factors for TLS development and implementation of adequate preventive measures remains the most critical component of its medical management. In general, these consist of vigilant laboratory and clinical monitoring, vigorous IV hydration, urate-lowering therapy, avoidance of exogenous potassium, use of phosphate binders, and - in high-risk cases - considering cytoreduction before the start of the aggressive agent or a gradual escalation of its dose. Key Messages: In patients with a high risk of TLS, cytotoxic chemotherapy should be given in the facility with ready access to dialysis and a treatment plan discussed with the nephrology team. In the case of hyperkalemia, severe hyperphosphatemia or acidosis, and fluid overload unresponsive to diuretic therapy, the early renal replacement therapy (RRT) should be considered. One must remember that in TLS, the threshold for RRT initiation may be lower than in other clinical situations since the process of cell breakdown is ongoing, and rapid increases in serum electrolytes cannot be predicted.
Asunto(s)
Síndrome de Lisis Tumoral/prevención & control , Síndrome de Lisis Tumoral/terapia , Lesión Renal Aguda/complicaciones , Animales , Manejo de la Enfermedad , Humanos , Hiperpotasemia/complicaciones , Hiperfosfatemia/complicaciones , Hiperuricemia/complicaciones , Incidencia , Factores de Riesgo , Síndrome de Lisis Tumoral/complicaciones , Síndrome de Lisis Tumoral/etiologíaRESUMEN
The tumor lysis syndrome represents a potentially lethal complication caused by the massive release of nucleic acids, potassium and phosphate into the circulation as a result of the lysis of neoplastic cells, which are characterized by a rapid proliferation capacity and high sensitivity to drugs. This may occur spontaneously prior to the start of treatment, becoming worse after the initiation of chemotherapy. It presents a high mortality; its prevention continues being the most important therapeutic measure. The clinical picture is characterized by the existence of hydroelectrolytic metabolism disorders, in particular hyperkalemia, hyperphosphatemia and hyperuricemia and by the appearance of an acute renal lesion. Adequate therapeutic intervention involves intravenous hydration and measures to prevent or correct metabolic alterations. This article proposes guidelines to follow both in the diagnostic stage and in the treatment of this complication.
El síndrome de lisis tumoral representa una complicación potencialmente letal provocada por la liberación masiva de ácidos nucleicos, potasio y fosfato hacia la circulación como resultado de la lisis de células neoplásicas, las cuales se caracterizan por una rápida capacidad de proliferación y alta sensibilidad a fármacos. Esto puede ocurrir de forma espontánea antes del inicio del tratamiento y agravarse luego de haberse iniciado la quimioterapia. Presenta una alta mortalidad. Su prevención continúa siendo la medida terapéutica más importante. El cuadro clínico se caracteriza por la existencia de trastornos del metabolismo hidroelectrolítico, en particular, hipercalemia, hiperfosfatemia e hiperuricemia y por la aparición de una lesión renal aguda. Una adecuada intervención terapéutica implica hidratación intravenosa y medidas para prevenir o corregir las alteraciones metabólicas. En este artículo, se proponen lineamientos para seguir tanto en la etapa diagnóstica como en el tratamiento de esta complicación.